Adcendo Completes $135 Million Series B to Boost ADC Pipeline
Deal News | Nov 25, 2024 | PR Newswire Cision Adcendo
In a significant move to boost its innovative ADC pipeline, Adcendo ApS has announced the completion of its oversubscribed $135 million Series B financing. This round, led by TCGX and featuring new investments from TPG Life Sciences Innovations, Orbimed Advisors, and other notable partners, underscores the strong industry confidence in Adcendo’s potential to revolutionize the treatment of cancers with high unmet medical needs. The funds will be directed towards advancing and clinically validating the company's suite of antibody-drug conjugates, aiming to address treatment gaps for solid tumors. Key players on Adcendo's new Board of Directors include individuals from RA Capital, Novo Holdings, and Pontifax Venture Capital, signaling a robust strategic direction. The accomplishment highlights Adcendo’s ambition to drive forward cancer therapies through scientific innovation.
Sectors
- Biotechnology
- Healthcare Investment
Geography
- Denmark – Adcendo, the biotech firm completing the financing round, is based in Copenhagen, Denmark.
- United States – Several investors in the financing round, including TCGX and other notable partners, are based in the United States, indicating significant US involvement in the investment.
Industry
- Biotechnology – The article discusses Adcendo's efforts in developing innovative antibody-drug conjugates (ADCs) for cancer treatment, a key activity within the biotechnology sector.
- Healthcare Investment – The funding round led by TCGX and other investors is a significant investment move within the healthcare sector, emphasizing funding for innovative cancer treatments.
Financials
- $135 million – The total amount raised in Adcendo's Series B financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Adcendo ApS | Target Company | Company | A Danish biotech company focused on developing ADCs for cancer treatment. |
| TCGX | Lead Investor | Company | A healthcare investment firm that led the Series B funding round. |
| TPG Life Sciences Innovations | Investor | Company | Participated as a new investor in the Series B funding round. |
| Orbimed Advisors | Investor | Company | Participated as a new investor in the Series B funding round. |
| RA Capital Management | Investor | Company | An existing investor in the Series B funding round. |
| Novo Holdings | Investor | Company | An existing investor participating in the funding round. |
| Michael Pehl | CEO of Adcendo | Person | Chief Executive Officer of Adcendo. |
| Cariad Chester | Managing Partner of TCGX | Person | Provided commentary on the impact of ADCs in cancer treatment. |